Tech entrepreneur Bryan Johnson announced a new focus on extending the lifespan of canines after adopting a Belgian Malinois named Katara.
From human anti‑aging to canine longevity
Johnson has spent years and millions on slowing human ageing, championing a “Don’t die” mantra. His recent shift stems from a personal bond with his new companion, which he says sparked a curiosity about how far lifespan science can go for pets.
Before turning his attention to dogs, Johnson built a reputation as a biohacker who publicly shares detailed protocols on sleep, nutrition, and supplementation, encouraging a community of followers to track every biometric metric. The same obsessive data‑driven approach now underpins his plan for Katara, illustrating how his human‑focused experiments are being repurposed for a non‑human subject.
What the plan looks for the new guard
Katara, who will turn two in October, arrived as a trained guard for Johnson, who claims he receives frequent death threats. “I get quite a few death threats, and so she is my guard,” he told a venture‑capitalist interviewer.
The pair have spent the past month traveling together, and Johnson says the pet will become “the most measured” in the world. He intends to apply the same rigorous data collection and interventions he shares with his followers to the animal.
He has not announced a separate company for the effort, emphasizing that the animal will undergo a suite of longevity therapies while remaining his personal companion.
During a recent longevity event in San Francisco, Katara was highlighted as a tangible example of Johnson’s vision, drawing attention from both investors and scientists who are watching how the experiment unfolds in a public forum.
Johnson’s description of the upcoming regimen includes continuous monitoring of metabolic markers, cardiovascular function, and cognitive performance, mirroring the telemetry dashboards he maintains for himself. By treating the dog as a living data set, he hopes to generate a granular timeline of how each intervention influences aging trajectories.
Related: Delhi CNG price up ₹3.89 per kg
Johnson argues that many commercial pet foods contain excessive harmful compounds, describing them as “things that glue your organs together.” He suggests owners could improve health by focusing on cleaner diets, though he offers no specific formula.
He also points out that advances in canine health could benefit people because of physiological similarities. “It’s remarkable how much dogs and humans have in common,” he said, noting that swapping species in research literature reveals many parallels.
The regulatory path for veterinary treatments is notably shorter than for humans. Drug approval timelines for canines can be a fraction of those for people, allowing faster scientific cycles.
Start‑ups such as Loyal are already pursuing FDA‑approved lifespan‑extension drugs for pets, while Rejuvenate Bio explores gene‑therapy approaches targeting age‑related conditions like cancer and arthritis.
Owners tend to invest heavily in their companions’ well‑being, often more so than in their own health. Johnson expects that this willingness will make adoption of advanced care straightforward.
He emphasizes that the willingness of pet owners to fund cutting‑edge therapies could accelerate the commercial pipeline, creating a feedback loop where successful canine trials attract additional capital and drive further innovation.
Looking ahead, the entrepreneur’s experiment may provide a proof‑of‑concept for rapid testing of anti‑aging interventions. If successful, the data could inform broader biomedical research, though the timeline and scalability remain uncertain.
Leave a Reply